TearLab Corporation, Reports Q3-10 Financial Results
SAN DIEGO, Nov. 11, 2010 (GLOBE NEWSWIRE) -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today reported its consolidated financial results for the quarter ended September 30, 2010. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles.
For the three months ended September 30, 2010, TearLab's net revenues were $210,000 as compared to $263,000 for the same period in 2009. The Company's loss for the third quarter of 2010 was approximately $2.2 million, or $0.15 per share. This compares to a loss of $0.7 million, or $0.07 per share, for the third quarter of 2009, which was positively impacted by a $0.6 million, or $0.06 per share, income tax recovery.
For the nine months ended September 30, 2010, TearLab's net revenues were $903,000 as compared to $603,000 for the same period in 2009. The Company's loss for the first three quarters of 2010 was approximately $5.8 million, or $0.42 per share. This compared to a loss of $2.7 million, or $0.27 per share, for the first three quarters of 2009, which was positively impacted by a $2 million, or $0.20 per share, income tax recovery."We achieved the second of our three major milestones in the third quarter – reimbursement for our TearLab® Osmolarity Test in the U.S. at a rate of $24.01 per eye," commented Elias Vamvakas, TearLab's Chief Executive Officer. Mr. Vamvakas continued, "We are very excited about this important accomplishment and continue to wait for the realization of our third and final major milestone – receipt of CLIA waiver certificate. We believe the combination of reimbursement and CLIA waiver is key to both driving the widespread use and commercial success of the TearLab® Osmolarity System in the U.S. and to maximizing penetration of the European and Canadian markets."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV